Tolterodine for the treatment of urge urinary incontinence. (October 2013)

• Record Type: Journal Article
• Authors: Elterman, Dean S; Chughtai, Bilal; Kaplan, Steven A; Barkin, Jack
• Is Part Of: Expert opinion on pharmacotherapy. Volume 14:Number 14(2013)
• Page Start: 1987
• Page End: 1991
• Publication Date: 2013-10
• Subjects: Detrol -- incontinence -- overactive bladder -- tolterodine -- urge urinary incontinence; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1517/14656566.2013.823158
• Languages: English
• ISSNs: 1465-6566

Abstract

Abstract : Introduction: Overactive bladder (OAB) and its resultant urge urinary incontinence (UUI) are significant problems that medically, psychologically and financially affect people. The constellation of symptoms comprising OAB affects ∼ 16% of the adult population and its prevalence increases with aging. The typical class of medications used to treat OAB is antimuscarinics. Areas covered: OAB medications, with a focus ontolterodine for the treatment of UUI are reviewed. A thorough review of English language literature using EMBASE/Medline and PubMed has been performed. Expert opinion: Tolterodine provides a reasonable starting point when treating patients with OAB and UUI. Efficacy and tolerability are generally comparable between tolterodine and other newer antimuscarinics. Tolterodine is a good option as part of the algorithm in the treatment of OAB and UUI.